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Antisense oligos complementary to the 5*-end, but
not to the 3*-end, of the estrogen receptor (ER)
messenger RNA caused a paradox accumulation
of ER protein in MCF-7 cells. The same effect was
observed after treatment of the cells with the cor-
responding sense oligos. The oligos interfering
with ER down-regulation were demonstrated to
specifically bind the ER with affinities in the nano-
molar range. It is, therefore, proposed that the ER
up-regulation induced by the oligos might be due
to squelching of the ER (or ER-inducible proteins)
from their binding site located in the 5*-end of the
ER gene. We also report that transcriptionally in-
active ER mutants can undergo down-regulation,
and that in denaturing gels, the migration profile of
ER-oligo and ER-estrogen-responsive element
complexes are dissimilar. We, therefore, propose
that ER can interact with DNA in different ways and
at different binding sites. These observations
might have important pharmacological conse-
quences, since specific drugs could be devised to
induce the ER conformation necessary to perform
only selected tasks of the ER transcriptional rep-
ertoire. (Molecular Endocrinology 11: 938–949,
1997)
INTRODUCTION
17b-Estradiol (E2) exerts its physiological effects on
target tissues by interacting with its cognate estrogen
receptor (ER), which is a member of a superfamily of
ligand-regulated transcription factors (1–3). Several
lines of evidence prove that after steroid binding, the
hormone-receptor complex interacts with specific
DNA target sequences, named estrogen-responsive
elements (ERE), which are located in the promoter of
estrogen-responsive genes (4–6). The activity of the
hormone-receptor complex can then be further mod-
ulated by a series of proteins acting as coactivators or
as repressors (7–10).
The concentration of ER is an important determinant
of cellular responsiveness to steroids, as suggested by
the observation that in mammals, ER expression fluc-
tuates in a spatial-temporal fashion in response to a
variety of endocrine stimuli. Further support for this
view is provided by studies at the cellular level, dem-
onstrating that receptor expression above a specific
concentration threshold is required for ER-mediated
events to occur (11, 12).
Due to the involvement of estrogens in an increasing
number of pathologies (13, 14), the study of receptor
regulation may have relevant pharmacological and
therapeutical consequences. To date, a limited num-
ber of studies have addressed the mechanisms of ER
regulation, which remain elusive. It is known that ER
intracellular content may be regulated by selected hor-
monal signals (e.g. the heterologous down-regulation
induced by progesterone) (15). In the majority of ani-
mal cells and tissues studied, the ER concentration is
under a control primarily exerted by estrogens through
a process termed autologous down-regulation or au-
tologous up-regulation depending on the tissue being
considered (16–18). The experimental evidence ob-
tained to date seems to indicate that in cells of cancer
origin, the activated ER is an integral part of this reg-
ulatory process. Saceda et al. (19) showed that at least
part of the autologous down-regulation is associated
with a decrease in the cell content of ER messenger
RNA (mRNA); this, in turn, results from a decreased ER
gene transcription rate in a process that is cyclohexi-
mide resistant and hormone concentration dependent.
The model devised to explain these findings invokes
an interaction of the ER with its own gene, similar to
the mechanism by which this same transcription factor
regulates any other target gene (20, 21). The activated
ER, therefore, would bind selected regions in the pro-
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moter of its own gene, preventing its further transcrip-
tion. The promoter of the ER gene, however, lacks the
canonical ERE; this suggests that a novel mechanism
of ER-DNA interaction may be involved.
To study the effect of estrogen on ER turnover, we
used antisense oligonucleotides (aODN) (22, 23) as
specific blockers of ER mRNA translation (24–26). It
is well known that many variables are involved in the
mechanism of action of aODN, and systematic stud-
ies on these variables in eukaryotic systems are still
lacking; it is, then, difficult to predict the best targets
for aODN. To select the most active oligos, a series
of molecules was synthesized and tested in a cell
line expressing ER (MCF-7 cells). Contrary to our
expectations, none of the antisense oligonucleo-
tides used was able to block ER synthesis, whereas
two of them caused a significant increase in the ER
protein content. In addition, ER up-regulation was
observed with oligos complementary (sense) to the
aODNs tested.
These results indicated that the physiological ma-
chinery responsible for maintaining the intracellular ER
levels could be offset by the presence of selected DNA
sequences. This prompted us to further investigate the
mechanisms underlying ER up-regulation mediated by
aODNs.
RESULTS
Selected Sense and Antisense Oligonucleotides
Increase ER Protein Content in MCF-7 Cells
Four antisense molecules corresponding to translated
and untranslated 59 regions of the ER mRNA (Fig. 1A)
and their complementary counterparts (sense) were
tested in MCF-7 cells. The sequences selected for the
initial studies were as follows: oligo1 (nucleotides
2117/299), GAC ATG CGC TGC GTC GCC; oligo2
(nucleotides 495/512), GCC AGT ACC AAT GAC AAG;
oligo3 (nucleotides 1140/1157), TGT GCC TGG CTA
GAG ATC; and oligo4 (nucleotides 4134/4151), GGG
TCA GTG GGT TCT TTT. Care was taken to avoid
homologies between the chosen sequences and other
mRNAs deposited in EMBL and GenBank databases
(with special attention to the mRNAs of the receptor
superfamily members).
Fig. 1. Effects of Antisense and Sense Oligonucleotides on ER Protein Content in MCF-7 Cells
A, ER cDNA target sequences: oligo1 (nucleotides 2117/299), GAC ATG CGC TGC GTC GCC; oligo2 (nucleotides 495/512),
GCC AGT ACC AAT GAC AAG; oligo3 (nucleotides 1140/1157), TGT GCC TGG CTA GAG ATC; and oligo4 (nucleotides
4134/4151), GGG TCA GTG GGT TCT TTT. B, Left, ER content was measured by EIA in extracts of MCF-7 cells treated for 48 h
with 1 nM E2 in the absence or presence of each of the oligos listed in A (14 mM, final concentration). The bars represent the mean 6
SEM of a minimum of eight independent experiments performed in duplicate. *, P , 0.05; **, P , 0.01 (vs. controls, by ANOVA
followed by Fisher’s test). B, Right, Oligo2-induced ER up-regulation as assessed by Western blotting. MCF-7 cells were treated
for 48 h with either 10 nM E2 or 14 mM ssoligo2. Three hundred micrograms of whole cell extracts were immunoprecipitated and
then run on SDS-PAGE (10% T) and analyzed by Western blotting using the anti-human ER antibody H222. Arrows indicate the
position of the 67-kDa ER polypeptide as well as that of the heavy (H) and light (L) chains of IgG from the immunoprecipitation
step. The autoradiograph shows results representative of three separate experiments.
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The activity of the oligos on ER synthesis was de-
termined by enzyme immunoassay (EIA) quantitation
of ER protein content in cell lysates after 48-h treat-
ment with 14 mM oligonucleotides. Figure 1B, left,
shows that in MCF-7 treated with oligo1 and oligo2
(both sense and antisense), the ER content was 73–
107% higher than that in untreated control cells.
Oligo3 and oligo4 did not modify the ER concentration
with respect to that in controls.
Western blot analysis using the H222 antibody as a
probe (Fig. 1B, right) confirmed the increase in ER protein
in MCF-7. Forty-eight hours after oligo2 treatment (right
lane), the intensity of the specific 67-kDa ER band (arrow)
was 50–70% higher than that in controls (left lane). After
exposure to E2 (middle lane), its intensity was 30–40%
lower than that in controls. As the same amount of pro-
tein was subjected to immunoprecipitation, the strongly
reactive IgG bands (arrows) may be regarded as loading
and blotting controls. A number of bands, of lower Mr,
were detected in control and treated cell lysates. These
may correspond to either cross-reacting components or
intermediates in endocellular ER catabolism. The slight
discrepancy in the extent of up-regulation, as quanti-
tated by EIA or by densitometric scanning of Western
blots, was attributed to both the different sensitivities of
the two techniques and to the fact that the densitometric
analysis had been restricted to the 67-kDa band.
To explain the ER intracellular accumulation caused
by oligo1 and 2, we ruled out the hypothesis that this
could occur via an interaction of the active oligos with
the ER mRNA, reasoning that both sense and anti-
sense had the same effect; therefore, a direct pairing
with the mRNA sequence could not have occurred. An
alternative explanation was provided by recent reports
which postulated that intracellular receptors can con-
trol the transcriptional activity of their own genes by
interacting with negative hormone-responsive ele-
ments located in the promoter or within the gene-
coding sequence (20). If this were the case, the para-
dox effect observed with the oligonucleotides could
have been due to the squelching of ER from the pro-
moter of its own gene.
The observation that oligos promoting ER accumu-
lation blocked E2-induced down-regulation, whereas
the inactive oligos did not have any influence on the
autologous down-regulation event (as shown in Fig. 2),
further indicated that the oligos hindered the physio-
logical mechanisms of ER autologous down-regula-
tion.
Regardless of the represented strand (sense or an-
tisense), only oligos corresponding to the 59-region of
the ER complementary DNA (cDNA) were found to
up-regulate ER. Thus, it was conceivable that this
region was primarily involved in ER autologous down-
regulation. To test this possibility, we studied E2-in-
duced down-regulation in cells transiently transfected
with mutants of the mouse ER cDNA. COS-1 cells
were, therefore, transfected with the full-length mouse
cDNA (MOR 1–599), an in-frame deletion mutant of the
mouse ER cDNA lacking the activation domain AF-1
(MOR 182–599) and the DNA-binding domain mutant
C241A/C244A, which is transcriptionally inactive (27)
but, in our hands, binds DNA. As expected, E2 induced
decreases in ER mRNA (256%; Fig. 3B) and protein
(242%; Fig. 3A) when the full-length ER cDNA was
transfected. However, with the ER mutant lacking the
NH2-terminus region (MOR 182–599), E2 did not affect
ER synthesis. This observation further underscored
the hypothesis of a role in ER down-regulation of the
cDNA sequences encoding residues 1–182 of the
receptor.
Interestingly, E2 induced down-regulation of the
transcriptionally inactive ER mutant C241A/C244A of
the DNA-binding domain, and this effect was of the
same magnitude as that seen with the wild type
receptor.
To further investigate the mechanism of aODN-de-
pendent up-regulation, a series of experiments was
undertaken with the most active of the oligos tested,
oligo2.
Fig. 2. Blockage of Estrogen-Induced Down-Regulation of
ER by Oligos
MCF-7 cells were treated for 48 h with 10 nM E2, 14 mM
oligo, or both hormone and oligo. The sequences of the
oligos were homologous to different regions of the 59-end of
the ER cDNA as follows: oligo5 (nucleotides 302/320), GTG
TCT CCG AGC CCG CTG; and oligo6 (nucleotides 539/557),
TGG ACA GTA GCG AGT CAG. ER protein levels were de-
termined by autoradiographic scanning of films of four sep-
arate Western blots performed as described in Fig. 1. The
autoradiograph shows a representative experiment. The bars
represent the mean 6 SEM.
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Gel Mobility Assay Argues for a Direct Interaction
between ER and Oligo2
We first assessed by electrophoretic gel shift assay
(EMSA) whether a direct interaction between oligo2
and ER protein could occur. The oligo2 retardation on
gel, induced by ER, was compared with that of the
canonical target for ER, the ERE. All of the studies
were performed using MCF-7 nuclear extracts as the
source of ER.
With oligo2 (Fig. 4; A, antisense; B, sense; C, double
strand), we observed several retarded bands; only one
of these was competed off by cold oligo2 (arrow).
When other oligos, such as those previously shown
not to interfere with ER accumulation (e.g. oligo4) or
scrambled oligos, were used, none of the retarded
bands could be competed off (data not shown). We,
therefore, concluded that the binding between ER and
oligo2 (sense and antisense) was specific.
The binding affinities of ER for single (ss) and double
(ds) stranded oligo2 were evaluated by saturation
analysis, as described in Materials and Methods. The
data in Fig. 4 were obtained by plotting the integrated
areas from the densitometric scanning of the relevant
bands according to Ligand (28). The ds oligo2 bound
ER with higher affinity than the ss oligo2 (dsoligo2: Kd 5
42 nM; senseoligo2: Kd 5 139 nM; antisenseoligo2: Kd 5
423 nM). In all cases, however, the Kd values for
oligo2-ER interaction were significantly lower than
those for dsERE-ER (1.6 nM; Fig. 4D).
To prove that the shifts of 32P-labeled oligo ob-
served were indeed due to the binding to ER, we
checked whether the band corresponding to the
oligo-receptor complex was supershifted in the
presence of the specific anti-ER H222 antibody. As
shown in Fig. 5, with both dsoligo2 and senseoligo2 the
antibody caused a supershift of the complex com-
parable to that observed with ER-ERE. With anti-
senseoligo2 we observed a smear of the retarded
band, probably due to low affinity within the ER-
antisenseoligo2 complex. The inactive oligo, oligo5,
was not shifted in the presence of ER. To further
prove that ER was responsible for the supershift
reported above, we also tested nuclear extract from
COS-1 cells, transfected or not with ER cDNA. No
retarded band could be observed with extracts of
COS-1 cells not expressing ER (see Fig. 8).
Fig. 3. Effects of ER Deletions on the Autologous Down-Regulation of ER mRNA and ER Protein
COS cells were transfected with 0.5 mg/ml of plasmids containing either the wild type ER cDNA (MOR 1–599) or two mutated
forms, MOR 182–599 and MOR C241A/C244A. After treatment of the cells with 1 nM E2 for 48 h, the ER protein and ER mRNA
levels were measured as described in Materials and Methods. A, Left, Representative immunoblot developed with the anti-ER H222
antibody. The Mr of the stained bands are 67 kDa for 1–599 and C241A/C244A, and 47 kDa for 182–599. A, Right, Densitometric
analysis of ER protein levels after normalizing the data for bgal activity. B, Left, Agarose gel of the ER-RT PCR amplified DNA
stained with ethidium bromide. The Mr marker is HaeIII-cut pBR322 DNA. The size of the amplification products is 600 bp for
GAPDH and 218 bp for ER. B, Right, Densitometric analysis of the amplified product levels after normalization with the GAPDH,
which was used as an internal control. Data are expressed as the mean 6 SEM of three separate experiments. *, P , 0.01 vs.
controls, by ANOVA followed by Fisher’s test.
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Fig. 4. Affinities of Oligo2 and ERE for ER as Assessed by EMSA
Nuclear extracts were incubated with 32P-labeled ssantisense2 (A), sssense2 (B), dsoligo2 (C), and dsERE (D) in the absence (2) or
presence of decreasing concentrations of the corresponding unlabeled oligo (from 1 mM to 4 nM). Arrows indicate the bands
competed off by the unlabeled oligo. The time of exposure to the autoradiography films varied between 8 h (ER-ERE) and 3 days
(ER-oligos). The exposure time was selected to ensure that the signals were within the range of linearity for the densitometric
scanning. The binding parameters were calculated with the program Ligand (28). The [Total] concentration represents the total
amount of labeled and unlabeled oligo in the incubation mixture. The homologous competition curves were plotted according to
the Ligand program. This experiment was repeated three times with different receptor preparations, with superimposable results.
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Estrogens Do not Repress Transcription of the
p-oligo2-GL2B-Luciferase Reporter Gene
To assess whether the interaction between ER and
oligo2 resulted in transcriptional modulation, the
oligo2 sequence was cloned in the promoterless lucif-
erase vector pGL2B, which was analyzed in the ER-
negative HeLa cells by cotransactivation assay with or
without cotransfected ER. Figure 6 shows that with the
empty pGL2B promoter, in the presence of E2-acti-
vated ER, the luciferase activity (LUC) was very low
and not significantly higher than that in cells not ex-
pressing ER. The promoter containing oligo2 had over
2-fold higher basal transcription activity, and the pres-
ence of the unliganded receptor doubled LUC. The
increased LUC due to ER presence, however, could
not be modulated by E2 (at high concentration, 100
nM). Similar results were obtained with transfection of
empty or oligo2-containing pGL2B in MCF-7 cells
(data not shown). In these ER-expressing cells the
accumulation of LUC was almost 5-fold higher in
oligo2-pGL2B- than in pGL2B-transfected cells. Also
in this case, the presence of 100 nM E2 did not cause
any further accumulation of the reporter protein.
These results suggest that ER may bind oligo2,
causing increased transcription of its downstream
genes; this interaction, however, differs from the ER-
ERE interaction, which is characteristically sensitive to
the presence of the hormone (Fig. 6, right panel). It is
worth stressing that these findings do not comply with
the view of oligo2 representing a negative response
element.
Oligo2-ER Complex Migration across a
Transverse Urea Gradient
The experiments described above proved the specific
interaction of both ss- and dsoligo2 with ER. We further
compared the characteristics of oligo2-ER and
ERE-ER interaction by investigating the electro-
phoretic behaviors of these complexes under denatur-
ing conditions.
The migration across a transverse urea gradient, as
introduced by Creighton (29) correlates the unfolding
of a protein molecule to a reduction in its electro-
phoretic mobility. The typical transition from the high
to the low mobility form occurs over a defined interval
of the chaotrope concentration, and the overall curve
displays a sigmoidal shape. This technique may be
applied to the study of interacting systems; different
Fig. 5. Supershift of the ER-Oligonucleotide Complexes
Equal amounts of MCF-7 nuclear extracts were tested in a
supershift assay using DNA probes consisting of 32P-labeled
dsERE, dsoligo2, sssense2, ssantisense2, and dsoligo5 in the ab-
sence (2) or presence (1) of monoclonal antibody H222.
Fig. 6. Effect of Transient Transfection of ER on the Transcription of a Promoter Driven by Oligo2 or ERE
HeLa cells were transfected with the ER expression vector (1 mg) or mock plasmid together with either pGL2B plasmid or the
same plasmid containing the oligo2 sequence (1.5 mg). As a control for transcription efficiency, all samples were cotransfected
with 0.5 mg pCMV-bgal. Assays of luciferase and bgal were performed as described in Materials and Methods 48 h after addition
of the hormone (100 nM E2). All transfections were performed in triplicate. Bars represent the mean 6 SEM of two separate
experiments.
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profiles of migration are observed depending upon the
homo- or heteromultimeric nature of the complex (30).
We, therefore, ran a series of experiments aimed at
studying the behavior under denaturing conditions of
the ss- and dsoligo2 as well as dsERE once complexed
with ER.
Panels A–C in Fig. 7 compare the profiles of migra-
tion across increasing urea concentrations of ER-
dsERE and the complexes between ss- and dsoligo2
with ER. The end of the radioactive tracing corre-
sponds to the urea concentration at which 32P-labeled
oligo and protein dissociate. This occurs at urea con-
centrations of about 4 M for [32P]dsERE-ER, 3 M for both
[32P]sssense2 and [
32P]dsoligo2-ER, and around 1 M for
[32P]ssantisense2-ER. These figures prove the interac-
tion between dsERE and ER to be much stronger than
that between oligo2 and ER, in agreement with the Kd
values calculated by EMSA.
Further examination of the dissociation/denatur-
ation curves of the three forms of ER-oligo2 complex
shows a migration profile parallel to the application
trench (Fig. 7, A–C, bottom). This implies that recep-
tor-DNA dissociation occurs before any appreciable
unfolding of the molecule. On the contrary, the migra-
tion of the ER-[32P]dsERE complex slows down around
0.5 M urea (A-C, top), indicating that some unfolding
occurs (presumably outside the receptor domain bind-
ing [32P]dsERE) before the complex dissociates. The
unfolding of the ER molecule is thus likely to occur
stepwise. Under the selected experimental conditions,
however, we cannot actually monitor the behavior of
ER, but can do so for the DNA-ER complex, although
only up to the point of its dissociation.
In the unfolding assay the various domains within
the ER molecule appear to behave independently.
These data, therefore, support the view that [32P]dsERE
and oligo2 interact differently with the ER molecule.
Moreover, the various domains appear to be differen-
tially stabilized by the binding of their ligands. Exam-
ples of both features (ligand stabilization and stepwise
unfolding) have been previously described for model
systems (30–34).
Both the effective urea concentrations and the pe-
culiar shapes of the dissociation/denaturation curves
were evaluated in independent replicas of each run,
and the behavior of each form of oligo2 was compared
with that of ER-dsERE in experiments (middle section
of A–C) in which the reference and the test complexes
were migrated in the same gel from two parallel
trenches.
Evaluation of the Size of the ER [32P]dsoligo2
Complex
The data accumulated to date show that dsoligo2 and
ERE interact with ER differently. To determine whether
accessory proteins were participating in the establish-
ment of the oligo2-ER complex, we determined the
size of the ER-oligo2 complex according to the
method of Ferguson (35). Samples were run in gels of
different polyacrylamide concentrations (T%) along
with Mr markers, as described in Materials and Meth-
ods. The larger the protein size, the more pronounced
was the decrease in protein mobility due to the in-
creasing sieving of the polyacrylamide matrix. The
log10 of protein mobility was plotted against the cor-
responding gel concentrations, and the slope of the
resulting straight line, defined as KR, was computed.
The molecular size of the test sample, inversely pro-
portional to KR, may be estimated by comparing its
mobility to that of a series of standards (Fig. 8).
Fig. 7. Electrophoresis across a Transverse Urea Gradient (0–8 M) of [32P]Oligo2 and [32P]ERE Complexes with ER
In each panel the behavior of a given oligonucleotide (sssense2 in A; ssantisense2 in B; dsoligo2 in C) is compared with that of dsERE.
The top sections show the dissociation/denaturation curve of dsERE-ER. The bottom sections show the curves for the various
oligo2 forms complexed with ER. The middle sections correspond to gels in which dsERE-ER and each specific oligo2-ER complex
were loaded in parallel troughs. The positions of application trenches are indicated by the dashed lines.
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Extracts of COS-1 transfected with ER-cDNA (ER-
COS) or MCF-7 used as a source of ER were incu-
bated with either [32P]dsERE or [
32P]dsoligo2. The anal-
ysis of both cell lines allowed cross-checking of the
molecular size of the ER complexed with each oligo in
cells constitutively expressing the hormone receptor
(MCF-7 cells) or overexpressing its exogenous cDNA
(COS-1 cells).
In untransfected COS-1 cells no retarded band
could be observed (Fig. 8, middle section). With ex-
tracts from ER-COS and MCF-7, the size of the ER-
dsERE complex was evaluated at 158 kDa, whereas
that of the ER-dsoligo2 complex corresponded to 143
kDa (Fig. 8B). The difference in size between the two
complexes is accounted for by the different lengths of
the two test oligonucleotides (33 nucleotides for dsERE
vs. 18 nucleotides for dsoligo2).
These figures, therefore, indicate that both oligonu-
cleotides bound either the dimeric form of the acti-
vated ER or its monomeric form plus an accessory
protein with a Mr around 67 kDa; no sign of different
migrations of the complexes from the two cell lines
could be detected.
DISCUSSION
The present study stems from the observation of a
paradoxical increase in ER content in MCF-7 cells
treated with oligonucleotides aimed at blocking ER
mRNA translation. Our results are in agreement with
those of a previous study by Williard et al. (36), in
which ER activity was demonstrated to be signifi-
cantly increased in cells expressing antisense ER
RNA.
It could be hypothesized that the effects observed
in the presence of oligonucleotides are linked to the
mechanism of ER autologous down-regulation,
which, according to Kaneko et al. (20) and Burnstein
et al. (21), occurs via a transcriptional repression
exerted by estrogen (or glucocorticoid) receptors on
the ER (or glucocorticoid receptor) genes. This ef-
fect would be mediated by specific DNA sequences,
acting similarly to the negative response elements
well characterized for glucocorticoid and thyroid
hormone receptors (37). In this perspective, the oli-
gos we describe would compete with the target
gene for ER, thereby decreasing the efficacy of ER
repression. In agreement with this hypothesis is the
finding that ER specifically binds oligos 1 and 6
(data not shown) and oligo2, which are active in
determining the receptor up-regulation, and it does
not interact with the inactive oligos (oligos 3, 4, and
5). However, a number of other observations argue
against the hypothesis of ER acting as a repressor:
1) the oligos determining ER up-regulation have a
sequence quite dissimilar from one another and cer-
tainly very different from any ERE described to date;
2) autologous down-regulation of the ER was ob-
served with the ER mutant C241A/C244A, which is
transcriptionally inactive; 3) the activity of a reporter
gene controlled by a promoter containing oligo2
failed to show any negative transcriptional activity of
ER. Indeed, the transcription from this promoter was
slightly increased in the presence of ER and was
hormone independent. ER, therefore, seems to
modulate the transcription of its own gene via an
alternative mechanism.
The gel shift analysis carried out under denaturing
and nondenaturing conditions suggests that ER in-
teracts differently with oligo2 and ERE. The migra-
tion across the urea gradient clearly shows that the
binding to dsoligo2 prevents the change in ER con-
formation observed at about 0.5 M urea with the
Fig. 8. Evaluation of the Molecular Sizes of the Complexes
between ER and dsoligo2 by Analysis of the Electrophoretic
Migration Data according to the Method of Ferguson
Nuclear extracts from MCF-7 and ER-COS cells were run
after incubation with either [32P]dsERE or [
32P]dsoligo2. A,
Comparison of their migration in 4% T (left) and 8% T (right)
polyacrylamide gels. In the middle, a COS-1 nuclear extract
is shown as a negative control. The horizontal ticks mark the
positions of the molecular size markers: A, a-lactoglobulin; B,
carbonic anhydrase; C, BSA monomer; D, BSA dimer; and E,
BSA trimer. In B, the molecular sizes of the complexes are
assessed by plotting, according to the method of Ferguson,
Mr vs. retardation coefficients (slope of the curve correlating
log10 migration with the percentage of T in the polyacrylamide
matrix).
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ER-ERE complex. In addition, ERE competes for
binding to the receptor with all forms of oligo2, while
the opposite does not apply to oligo2, even for very
high concentration ratios (up to a 10,000-fold molar
excess; data not shown). It is, therefore, conceivable
that oligo2 and ERE do not bind the same ER do-
main; however, the binding to ERE hinders the
oligo2-binding site.
On the basis of what we described above, it could
be proposed that autologous down-regulation of ER
occurs via a novel mechanism of receptor-DNA inter-
action that is unrelated to the mechanism of hormone-
dependent transcriptional repression. This is further
supported by the fact that full antagonists of the ER
receptor, such as ICI 182,780, which allows the for-
mation of transcriptionally unproductive ER-ERE com-
plexes, are extremely efficient in causing ER down-
regulation (38, 39).
The fact that ER uses two different mechanisms of
DNA interaction to induce the transcription of target
genes and the repression of its own is not totally
surprising. It is quite possible that, once activated
by the cognate hormone, ER binds the responsive
elements to modulate the transcription of the target
genes, which are then inactivated by still unde-
scribed modifications. In this transcriptionally inac-
tive form, however, the receptor could acquire the
capability to interact, directly or via specific adapter
proteins, with its own gene to hinder its own tran-
scription. Supporting this view is the observation
that the phenomenon of down-regulation requires a
longer time than transcription to start. Our study did
not allow us to prove that accessory proteins take
part in binding of the ER to oligo2; in the migration
study performed according to the method of Fergu-
son (35), no distinguishable difference in size for the
complexes ER-oligo2 and ER-ERE was observed
regardless of the ER protein source (MCF-7 or
COS-1 transfected with ER). We hypothesize, there-
fore, that a homodimer of the receptor is responsible
for binding the ER gene; however, we cannot rule
out the hypothesis that in the complex with oligo2,
ER heterodimerizes with a protein with a Mr very
close to 67 kDa. Other reports on steroid receptors
(estrogen or progesterone) suggest that they can
modulate transcriptional events in a conformation
that does not require the presence of the DNA-
binding domain (40, 41).
A better understanding of this phenomenon might
have important pharmacological consequences, as
certain drugs could be devised to induce the specific
conformation aimed at carrying out a selected task.
The squelching assay with short oligonucleotide se-
quences homologous to the 59-segment of the ER
gene here described can be used to identify the tar-
gets of ER in autologous regulation and might be
relevant for clarification of the mechanism of ER
activity.
MATERIALS AND METHODS
Chemicals
Oligodeoxynucleotides were synthesized by Pharmacia Bio-
tech (Cambridge, UK). E2 was purchased from Sigma Chem-
ical Co. (St. Louis, MO). Cell culture reagents were obtained
from Flow Laboratories (Irvine, Scotland), Merck (Darmstadt,
Germany), and Life Technologies (Madison, WI). All other
reagents were molecular biology grade from Boehringer
Mannheim (Mannheim, Germany) and Merck unless other-
wise specified. Plasticware was obtained from Corning
(Corning, NY). RPMI 1640 and DMEM were purchased from
Sigma and Life Technologies (Paisely, UK), respectively. FBS
was obtained from Imperial (Unipath, UK). The expression
vector containing the human ER cDNA was provided by G.
Greene (University of Chicago, Chicago, IL) (42). The pUHC-
b-galactosidase (pUHC-bgal) was obtained from Promega.
ER mutants (38) were a gift from M. Parker.
Cell Culture
MCF-7 and COS-1 cells were grown in RPMI 1640 without
phenol red (Sigma, Milan, Italy) supplemented with 10%
charcoal-stripped FBS (DCC-FBS) (43). The cells were grown
in 100-mm petri dishes containing 10 ml culture medium.
About 1 3 106 cells were seeded/dish. The medium was
replaced every 4 days. Once a week, at semiconfluence, the
cells were split by treatment with trypsin (0.5 g/liter trypsin
and 0.2 g/liter EDTA) for 5 min at 37 C and resuspension in
fresh medium at a 1:20 dilution.
To test aODN activity, the cells were plated in 2.5-cm
wells (0.3 3 106 cell/well) and grown in phenol red-free
medium supplemented with 10% DCC-FBS. To limit the
degradation of the oligonucleotides by serum nucleases,
the FBS was heat inactivated at 65 C for 45 min (44). As
some degradation still occurred, as evaluated by PAGE, 14
mM nucleotides, dissolved in water, were added every 24 h.
MCF-7 cells were treated in parallel with several oligonu-
cleotides for 48 h. E2 was diluted in phenol red-free RPMI
at a final concentration of 1028 M/0.01% ethanol; 0.01%
ethanol was added to controls. ER quantitation was per-
formed in duplicate on high salt buffer extracts as previ-
ously described (26). ER content was quantified immu-
noenzymatically (ER-EIA kit, Abbott Laboratory, North
Chicago, IL) and normalized for the protein concentration,
as evaluated by Bradford’s method (45).
Transient Transfection Assay
E2-Induced Down-Regulation in COS Cells Transfected
with ER Twenty-four hours before transfection, 2 3 105
cells were plated in 2.5-cm wells containing 3 ml phenol
red-free RPMI 1640 medium supplemented with 10% DCC-
FBS. Six hours before addition of the CaPO4-DNA mixture,
the medium was replaced with DMEM with 10% DCC-FBS
containing 1 nM E2 or its solvent. In a typical experiment, the
cells were transfected using the following DNA concentra-
tions: 200 ml of a suspension of 0.05 mg/ml ER cDNA (or its
mutants), 0.05 mg/ml of the gene pUHC-bgal (as control for
transfection efficiency), and 0.12 mg/ml carrier DNA
(pGEM3z) in 1.8 ml medium. Sixteen hours after addition of
the precipitate, the medium was discarded and, after a few
washes with RPMI 1640, replaced with phenol red-free RPMI
1640 containing 1% DCC-FBS (with or without E2). Forty-
eight hours later, the medium was removed, the cells were
washed several times with PBS, and cell extracts were pre-
pared according to the method of Patrone et al. (46). bGal
activity was measured as previously reported (47). The pro-
tein content was measured according to the method of Brad-
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ford (45). Each experiment was repeated at least three times
on duplicate samples.
Assessment of ER Transactivation Activity of oligo2-
pGL2B For plasmid construction, the oligo2-pGL2B-lucif-
erase reporter was generated by insertion of dsoligo2 into the
SmaI site of the pGL2B plasmid (Promega).
Transfections Cells were plated at high density, as de-
scribed above (HeLa cells were grown in Modified Eagle’s
Medium). Cells were transfected with 1.5 mg oligo2-pGL2B-
luciferase (or pGL2B-luciferase), 0.5 mg pCMV-bgal, and 1 mg
ER expression plasmid or mock plasmid. All transfections
were performed in triplicate. After a 2-h transfection, the cells
were washed, and fresh medium containing either 1 nM E2 or
its solvent was added. After 48-h incubation, luciferase and
bgal were measured as previously described (48).
Gel Retardation Assay
The EMSA was performed as described by Bettini et al. (49).
The oligonucleotides were labeled by incorporation of
[g-32P]ATP (Amersham, Aylesbury, UK) with T4 kinase (Pro-
mega) to a specific activity of about 108 dpm/mg DNA. The
32P-labeled oligos (;10,000 cpm/lane) were incubated with
the nuclear extract (5–8 mg protein) in the presence of 1 mg
HaeIII-cut pBR322 for about 15 min at 4 C before adding the
competing cold nucleotides. The receptor concentration was
chosen to ensure a ratio between the oligo bound and total
oligo lower than 10% as required by Munson and Rodbard
(28). The binding reaction was then carried to equilibrium with
an incubation time of 20 min at room temperature. Addition of
the DNA dye [50% (vol/vol) glycerol, 0.25% (wt/v) bromophe-
nol blue, and 0.25% (wt/v) xylene cyanol] ended the reaction.
The entire incubation mixture (10 ml) was loaded onto non-
denaturing polyacrylamide gels (6% T and 2.5% C). The gels
were run with TBE buffer (90 mM Tris-HCl, 90 mM boric acid,
and 10 mM EDTA) for about 2 h. Gels were then dried with a
gel dryer (Slab Dryer, Savant, Holbrook, NY) and exposed to
x-ray film (Kodak RP, Eastman Kodak, Rochester, NY) for
about 16 h. The gel retardation analysis was performed on
several samples to which the same unlabeled competitor was
added in various concentrations (4 nM to 1 mM) in the pres-
ence of a fixed concentration of [32P]oligo. After densitomet-
ric scanning of the autoradiograph, the results were evalu-
ated as homologous competition models by the program
Ligand (to calculate the apparent affinity of ER for the DNA)
(28).
Bandshift Assay
The labeled probes (10,000 cpm/lane) were incubated with 2
mg MCF-7 nuclear extract in a buffer consisting of 10 mM
HEPES (pH 7.9), 100 mM KCl, 1 mM dithiothreitol, 0.5 mM
EDTA, 2.5 mM MgCl2, 6% glycerol, and 2% Ficoll. The reac-
tion was allowed to proceed at room temperature for 10 min.
The addition of the antibody (100 ng) was made before mixing
with the labeled probe. The samples were subjected to elec-
trophoresis (150 V at room temperature) in a nondenaturing
5% T polyacrylamide slabs in 0.5 3 Tris-borate-EDTA for 4 h.
Electrophoresis across a Transverse Urea Gradient
The complexes between hormone-saturated ER and the four
oligonucleotides were run across 0- to 8-M urea gradients
according to the method of Creighton (29). The polyacryl-
amide matrix had a concentration of 6.5% T and 4% C in TBE
buffer. The gels were cast against GelBond PAG foils (FMC,
Rockville, MD) in a 0.5-mm thick cassette (18–1013-74, Phar-
macia, Uppsala, Sweden); one or two parallel sample appli-
cation trenches were shaped with 170 3 2.5-mm2 strips of
embossing tape glued to the glass plate. A 4-ml concentra-
tion plateau of the 8-M urea mix was poured first, followed by
an 8-ml urea gradient delivered from a two-chamber mixer
(18–1019-87, Pharmacia) and a further concentration plateau
from the solution without urea. The gels were run in a hori-
zontal electrophoresis chamber (Multiphor, LKB Pharmacia).
To minimize radioactive contamination, according to the sug-
gestion of Kleine et al. (50), 1% agarose strips in 4 3 TBS (5 3
15 3 250 mm3) were substituted for electrodic solutions and
paper wicks. Under a constant voltage of 100 V/11 cm and at
a temperature of 15 C, the run of a single sample lasted 80
min. When the behavior of a different oligonucleotide com-
plex was compared with that of ERE, the latter was applied
first in the more cathodal trench, whereas the second sample
was loaded after a 30-min run, once the free oligonucleotide
had migrated past the more anodal trench. The sample vol-
ume was 130 ml, containing 20 mg of nuclear proteins (in 20
ml), 75 ml EMSA buffer (48), 1 mg HaeIII-cut pBR322 (in 1 ml),
2 ml [32P]oligo to a specific activity of about 1028 dpm/mg
DNA, and 13 ml H2O; the mixture was incubated for 30 min at
room temperature, then added with 22 ml DNA dye [50%
(vol/vol) glycerol, 0.25% (wt/vol) bromophenol blue, and
0.25% (wt/vol) xylene cyanol].
The Ferguson Plot
The molecular size of ER-oligonucleotide complexes was
evaluated on polyacrylamide gels (4% and 8% T), cast in TBE
buffer according to the method of Ferguson (34). The 250 3
125 3 0.5-mm3 slabs, supported on GelBond PAG foils, were
polymerized in halves at the two gel concentrations. Sample
and marker proteins (a-lactalbumin, carbonic anhydrase, and
BSA plus ovalbumin, which, however, exhibited an anoma-
lous behavior in the presence of borate ions; all markers from
Sigma Chemical Co., St. Louis, MO) were dissolved in high
salt buffer; 7 ml were applied/lane, corresponding to 7 mg of
the markers and 5–8 mg of the nuclear proteins. The gels were
run at 15 C for 90 min in a Multiphor chamber (Pharmacia) at
100 V/11 cm. The marker proteins were stained with Coo-
massie blue R, whereas the ER-oligonucleotide complexes
were detected by autoradiography.
Western Analysis of the ER Protein
Sample preparation was the same for MCF-7 and COS-1
cells, except that MCF-7 lysates were first subjected to an
immunoprecipitation step, as previously reported (51). Thirty
micrograms of proteins were immunoprecipitated, then de-
natured and loaded onto a 10% SDS-polyacrylamide slab
gel. After electrophoretic migration, the proteins were trans-
ferred to Hybond-C Extra nitrocellulose (Amersham) in a
Trans-Blot apparatus (Bio-Rad, Hercules, CA). Blots were
stained with Red Ponceau (Sigma, St. Louis, MO) to assess
the efficiency of protein transfer. The filters were saturated for
16 h with 5% milk proteins and 0.2% Tween-20 in TBS (50
mM Tris and 150 mM NaCl) before incubation with the anti-ER
monoclonal antibody H222 (Abbott Laboratories, North Chi-
cago, IL). Immunoreactive proteins were detected after incu-
bation with a peroxidase-conjugated secondary antibody
(rabbit anti rat-IgG antibody, Vector Laboratories, Burlin-
game, CA) through ECL reaction (Amersham) and exposure
to Hyperfilm-MP (Amersham).
Semiquantitative Analysis of ER mRNA by reverse
transcription-PCR
Total cell RNA was isolated with the Bio/RNA-X Cell kit (Bio/
Gene, Kimbolton Cambs, UK) using 1 ml RNA-X reagent for
5–10 3 106 cells. One microgram of RNA was reverse tran-
scribed using oligo(deoxythymidine)12218 and Moloney mu-
rine leukemia virus reverse transcriptase (HT Biotechnology,
Cambridge, UK) as previously described (46). One tenth of
the reaction of cDNA was amplified in a 100-ml mixture con-
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taining 2.5 U DynaZyme-DNA polymerase (Finenzyme OY,
Espo, Finland), the buffer provided by Finenzyme, 0.2 mM
deoxy-NTP, and 100 pmol PCR primers, the 18-mers 59-AGC
GTG TCT CCG AGC CCG-39 and 59-TGC ACA GTA GCG
AGT CTC-39 for human ER. Fifty picomoles of a set of primers
for the constitutively expressed enzyme GAPDH (the 24-mers
59-CCA CCC ATG GCA AAT TCC ATG GCA-39 and 59-TCT
AGA CGG CAG GTC AGG TCC ACC-39) were used in each
reaction as an internal control for the amount of mRNA tran-
scribed and amplified. After denaturing at 94 C for 2 min, PCR
amplification was performed for 32 cycles (94 C for 15 sec, 48
C for 20 sec, and 72 C for 30 sec), followed by a final
extension step (72 C for 3 min). The duration and temperature
of the PCR cycles were experimentally optimized to fall into
the exponential phase of the amplification (52).
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